RELAY THERAPEUTICS INC (RLAY) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:RLAY • US75943R1023

9.15 USD
+0.16 (+1.78%)
At close: Feb 11, 2026
9.15 USD
0 (0%)
After Hours: 2/11/2026, 8:00:01 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to RLAY. RLAY was compared to 523 industry peers in the Biotechnology industry. While RLAY has a great health rating, there are worries on its profitability. While showing a medium growth rate, RLAY is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year RLAY has reported negative net income.
  • In the past year RLAY has reported a negative cash flow from operations.
  • RLAY had negative earnings in each of the past 5 years.
  • In the past 5 years RLAY always reported negative operating cash flow.
RLAY Yearly Net Income VS EBIT VS OCF VS FCFRLAY Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -100M -200M -300M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -44.42%, RLAY is in line with its industry, outperforming 55.45% of the companies in the same industry.
  • The Return On Equity of RLAY (-48.97%) is better than 67.11% of its industry peers.
Industry RankSector Rank
ROA -44.42%
ROE -48.97%
ROIC N/A
ROA(3y)-35.23%
ROA(5y)-34.11%
ROE(3y)-39.82%
ROE(5y)-38.03%
ROIC(3y)N/A
ROIC(5y)N/A
RLAY Yearly ROA, ROE, ROICRLAY Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -10 -20 -30 -40

1.3 Margins

  • RLAY does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RLAY Yearly Profit, Operating, Gross MarginsRLAY Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -5K -10K -15K -20K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. Health

2.1 Basic Checks

  • RLAY does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, RLAY has more shares outstanding
  • The number of shares outstanding for RLAY has been increased compared to 5 years ago.
  • There is no outstanding debt for RLAY. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
RLAY Yearly Shares OutstandingRLAY Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
RLAY Yearly Total Debt VS Total AssetsRLAY Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

  • An Altman-Z score of 10.37 indicates that RLAY is not in any danger for bankruptcy at the moment.
  • RLAY has a better Altman-Z score (10.37) than 82.22% of its industry peers.
  • RLAY has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 10.37
ROIC/WACCN/A
WACC12.37%
RLAY Yearly LT Debt VS Equity VS FCFRLAY Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M 800M

2.3 Liquidity

  • A Current Ratio of 19.14 indicates that RLAY has no problem at all paying its short term obligations.
  • RLAY has a Current ratio of 19.14. This is amongst the best in the industry. RLAY outperforms 96.18% of its industry peers.
  • RLAY has a Quick Ratio of 19.14. This indicates that RLAY is financially healthy and has no problem in meeting its short term obligations.
  • RLAY has a Quick ratio of 19.14. This is amongst the best in the industry. RLAY outperforms 96.18% of its industry peers.
Industry RankSector Rank
Current Ratio 19.14
Quick Ratio 19.14
RLAY Yearly Current Assets VS Current LiabilitesRLAY Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 32.95% over the past year.
  • The Revenue for RLAY has decreased by -76.50% in the past year. This is quite bad
  • Measured over the past years, RLAY shows a very strong growth in Revenue. The Revenue has been growing by 48.92% on average per year.
EPS 1Y (TTM)32.95%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%31.75%
Revenue 1Y (TTM)-76.5%
Revenue growth 3Y48.92%
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 4.69% on average over the next years.
  • Based on estimates for the next years, RLAY will show a very strong growth in Revenue. The Revenue will grow by 47.44% on average per year.
EPS Next Y20.69%
EPS Next 2Y13.36%
EPS Next 3Y8.32%
EPS Next 5Y4.69%
Revenue Next Year-24.27%
Revenue Next 2Y-28.59%
Revenue Next 3Y12.41%
Revenue Next 5Y47.44%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
RLAY Yearly Revenue VS EstimatesRLAY Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M 800M 1B
RLAY Yearly EPS VS EstimatesRLAY Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 -2 -3 -4

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for RLAY. In the last year negative earnings were reported.
  • Also next year RLAY is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RLAY Price Earnings VS Forward Price EarningsRLAY Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RLAY Per share dataRLAY EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y13.36%
EPS Next 3Y8.32%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • RLAY does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

RELAY THERAPEUTICS INC

NASDAQ:RLAY (2/11/2026, 8:00:01 PM)

After market: 9.15 0 (0%)

9.15

+0.16 (+1.78%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06
Earnings (Next)02-19
Inst Owners81.1%
Inst Owner Change-5.4%
Ins Owners1.32%
Ins Owner Change-1.62%
Market Cap1.59B
Revenue(TTM)8.36M
Net Income(TTM)-297.59M
Analysts85.56
Price Target14.84 (62.19%)
Short Float %15.75%
Short Ratio10.29
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)8.38%
Min EPS beat(2)-1.47%
Max EPS beat(2)18.23%
EPS beat(4)3
Avg EPS beat(4)11.45%
Min EPS beat(4)-1.47%
Max EPS beat(4)21.46%
EPS beat(8)7
Avg EPS beat(8)12.08%
EPS beat(12)10
Avg EPS beat(12)12.23%
EPS beat(16)11
Avg EPS beat(16)8.43%
Revenue beat(2)1
Avg Revenue beat(2)453.11%
Min Revenue beat(2)-100%
Max Revenue beat(2)1006.21%
Revenue beat(4)2
Avg Revenue beat(4)18997.6%
Min Revenue beat(4)-100%
Max Revenue beat(4)75184.3%
Revenue beat(8)3
Avg Revenue beat(8)11025.5%
Revenue beat(12)5
Avg Revenue beat(12)7887.85%
Revenue beat(16)6
Avg Revenue beat(16)5909.67%
PT rev (1m)-0.37%
PT rev (3m)6.95%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-6.17%
EPS NY rev (1m)-7.28%
EPS NY rev (3m)-9.48%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-22.22%
Revenue NY rev (1m)-0.42%
Revenue NY rev (3m)-5.77%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 189.79
P/FCF N/A
P/OCF N/A
P/B 2.61
P/tB 2.61
EV/EBITDA N/A
EPS(TTM)-1.75
EYN/A
EPS(NY)-1.71
Fwd EYN/A
FCF(TTM)-1.44
FCFYN/A
OCF(TTM)-1.43
OCFYN/A
SpS0.05
BVpS3.51
TBVpS3.51
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -44.42%
ROE -48.97%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-35.23%
ROA(5y)-34.11%
ROE(3y)-39.82%
ROE(5y)-38.03%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 9.53%
Cap/Sales 4.89%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 19.14
Quick Ratio 19.14
Altman-Z 10.37
F-Score4
WACC12.37%
ROIC/WACCN/A
Cap/Depr(3y)111.54%
Cap/Depr(5y)95.45%
Cap/Sales(3y)230.95%
Cap/Sales(5y)161.94%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)32.95%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%31.75%
EPS Next Y20.69%
EPS Next 2Y13.36%
EPS Next 3Y8.32%
EPS Next 5Y4.69%
Revenue 1Y (TTM)-76.5%
Revenue growth 3Y48.92%
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-24.27%
Revenue Next 2Y-28.59%
Revenue Next 3Y12.41%
Revenue Next 5Y47.44%
EBIT growth 1Y50.48%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year17.32%
EBIT Next 3Y8.07%
EBIT Next 5Y10.71%
FCF growth 1Y9.35%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y7.36%
OCF growth 3YN/A
OCF growth 5YN/A

RELAY THERAPEUTICS INC / RLAY FAQ

Can you provide the ChartMill fundamental rating for RELAY THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 4 / 10 to RLAY.


What is the valuation status for RLAY stock?

ChartMill assigns a valuation rating of 0 / 10 to RELAY THERAPEUTICS INC (RLAY). This can be considered as Overvalued.


What is the profitability of RLAY stock?

RELAY THERAPEUTICS INC (RLAY) has a profitability rating of 1 / 10.


What is the expected EPS growth for RELAY THERAPEUTICS INC (RLAY) stock?

The Earnings per Share (EPS) of RELAY THERAPEUTICS INC (RLAY) is expected to grow by 20.69% in the next year.